Related Experiment Video
Updated: Jun 22, 2025
Subcutaneous Infection of Methicillin Resistant Staphylococcus Aureus MRSA
Published on: February 9, 2011
Sophoricoside ameliorates methicillin-resistant Staphylococcus aureus-induced acute lung injury by inhibiting
Yaxian Wu1, Shuai He2, Yaru Zhang2
1Wuxi School of Medicine, Jiangnan University, Wuxi 214122, Jiangsu province, PR China; School of Food Science and Technology, Jiangnan University, Wuxi 214122, Jiangsu province, PR China.
Background:
The lack of effective treatments for methicillin-resistant Staphylococcus aureus (MRSA) infection, which often leads to severe acute lung injury (ALI), poses a grave threat to human life. Sophoricoside (SOP), an isoflavone glycoside abundant in the fruit of traditional Chinese herbal Sophora japonica l., showed anti-inflammatory effects against atopic dermatitis, allergic inflammation, and lipopolysaccharide-induced ALI. However, its effect and underlying mechanism on MRSA-induced ALI remain unclear.
Purpose:
The aim of this study is to assess the protective effect of SOP in MRSA-induced ALI and elucidate its underlying molecular mechanisms.
Methods:
In vivo experiments were conducted using wild-type mice to establish MRSA-induced ALI mouse model, and the effects of SOP on ALI were evaluated by hematoxylin-eosin staining, flow cytometry, quantitative real-time polymerase chain reaction, and several biochemical indicators. Adoptive transfer experiments and BTB and CNC homology 1 knockout (Bach1-/-) mice were also utilized in this study. In vitro studies employed murine macrophages RAW264.7 cells, primary bone marrow-derived macrophages (BMDMs), and primary lung macrophages to explore the underlying molecular mechanisms.
Results:
The administration of SOP ameliorated MRSA-induced ALI by improving pulmonary histological damages, reducing neutrophil infiltration, suppressing oxidative stress levels, and decreasing the expression of inflammatory cytokines. In isolation experiments with ALI mouse lung macrophages and macrophage adoptive transfer experiments, SOP prevented macrophage activation, thereby reducing the production of proinflammatory cytokines. In vitro experiments demonstrated that SOP decreased the expression of inflammatory mediators in lipoteichoic acid (LTA)-stimulated RAW264.7 cells, BMDMs, and primary lung macrophages. Additionally, SOP inhibited protein kinase B (Akt) phosphorylation and treatment with MK2206-a specific inhibitor of Akt-eliminated SOP's ability to suppress LTA-stimulated macrophage inflammation. Furthermore, stimulation with LTA or MRSA up-regulated Bach1 expression; however, deletion of Bach1 abolished the inhibitory effect of SOP on p-Akt activation as well as inflammation and ALI development.
Conclusion:
This study provides the first evidence that SOP effectively mitigates MRSA-induced ALI via suppressing macrophage activation through the inhibition of Bach1/Akt pathway. These findings highlight the potential of SOP as a novel therapeutic agent for treating MRSA-induced ALI.
Insights
Sophoricoside (SOP) effectively treats methicillin-resistant Staphylococcus aureus (MRSA)-induced acute lung injury (ALI) by inhibiting macrophage activation. This compound targets the Bach1/Akt pathway, offering a potential new therapy for MRSA infections.
Area of Science:
- Pharmacology
- Immunology
- Infectious Diseases
Background:
- Methicillin-resistant Staphylococcus aureus (MRSA) infections can cause severe acute lung injury (ALI), necessitating effective treatments.
- Sophoricoside (SOP), derived from Sophora japonica L., exhibits anti-inflammatory properties but its role in MRSA-induced ALI is unknown.
Purpose of the Study:
- To evaluate the protective effects of SOP against MRSA-induced ALI.
- To elucidate the molecular mechanisms underlying SOP's action in MRSA-induced ALI.
Main Methods:
- MRSA-induced ALI mouse models were established for in vivo analysis using histological, flow cytometry, and molecular assays.
- In vitro studies utilized macrophages (RAW264.7, BMDMs, primary lung macrophages) to investigate SOP's mechanism.
- Experiments included adoptive transfer and knockout mice (Bach1-/-) to confirm pathway involvement.
Main Results:
- SOP administration reduced lung damage, neutrophil infiltration, oxidative stress, and inflammatory cytokines in MRSA-induced ALI.
- SOP suppressed macrophage activation and pro-inflammatory cytokine production, both in vivo and in vitro.
- SOP inhibited the Bach1/Akt pathway, and Bach1 deletion abolished SOP's protective effects against ALI.
Conclusions:
- SOP demonstrates significant therapeutic potential for MRSA-induced ALI by inhibiting macrophage activation via the Bach1/Akt pathway.
- These findings support SOP as a promising novel therapeutic agent for MRSA-induced ALI.
